dermaliq – The Skin is our largest organ

The skin is our largest organ.

The skin is unique in many ways, but no other organ is so visible and demands so much attention and care in both diseased and healthy states.

About us

Dermaliq Therapeutics, Inc., is a dermatology and aesthetics company with a rich pipeline focused on follicular diseases and conditions. We are developing differentiated medical aesthetics, self-pay prescription, and OTC products.

Dermaliq’s mission is to develop a new generation of high-quality and user-friendly products with maximum efficacy and safety. Our unique “hyliQ^®” technology overcomes the “delivery barrier” and for the first time enables the adsorption of multiple attractive active ingredients and drugs into the follicle and skin, enabling the development of “first in class” and “best in class” treatment options.

THERAPEUTIC FOCUS

Medical dermatology, aesthetics and follicular diseases

Skin and hair disorders are a leading cause of nonfatal disease burden worldwide and have a significant impact on a person’s well-being, mental health, ability to function, and social participation.

Topical, localized delivery of active ingredients to skin and scalp is the preferred route of treatment in most patients, reducing the risk of systemic side effects. Dermaliq’s transformative hyliQ^® technology ushers in a new generation of topical products which offer not only superior dermal drug delivery for conditions like psoriasis and eczema but targeted delivery deep into hair follicles and sebaceous glands.

Specifically, hyliQ^® technology consists of novel lipophilic excipients with lowest viscosity and surface tension which enables rapid penetration into follicles and the formation of active ingredient depots in the associated glands. This opens new avenues for topical treatment of many challenging dermatological conditions, including:

Alopecia: Hair loss that can occur in various patterns, including alopecia areata (patches of baldness) or androgenetic alopecia (male or female pattern baldness).
Folliculitis: Inflammation of hair follicles, often caused by bacterial or fungal infections.
Hirsutism: Excessive hair growth in women in areas where men typically grow hair.
Acne vulgaris: A condition where pimple-like bumps or keloid scars (comedones, papules, pustules, nodules) develop in the face or on the back of the neck.

Technology

The evolutionary hyliQ^®– technology

hyliQ^®, the unique and proprietary technology owned by Dermaliq, is designed to provide cutaneous drug delivery with unmatched bioavailability for a wide range of pharmaceutical actives.

The technology enables the development of superior liquid therapeutic drugs and medical skin care products which are characterized by exceptional cosmetic properties.

hyliQ^® products do not require skin irritating excipients such as preservatives or penetration enhancers.

How it works

Proprietary hyliQ^® carrier molecules transport solubilized active ingredients through the stratum corneum, preferably into the epidermis, into glands, or into hair follicles. By selection of specific carrier molecules, we can customize the properties of our drug products, enhancing targeted penetration into the skin tissues, increasing efficacy and reducing unwanted side effects.

hyliQ^® – drug candidates

full dose is absorbed into skin and glands

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

Our Pipeline

Our goal is to establish a comprehensive pipeline of next-generation topical drugs and medical skin care products based on our proprietary hyliQ^® technology.

DLQ01

Androgenetic Alopecia

DLQ01 has the potential to become the leading next generation hair growth product. It is a liquid topical formulation of a prostaglandin (PG) F2alpha analog in hyliQ^® designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness.

DLQ01 Phase 2 data has impressively demonstrated its superior efficacy. The number of hairs in the target area increased effectively with high statistical significance compared to the vehicle. More than 80% of subjects responded with a positive change in hair growth. We are continuing clinical development based on a clear regulatory pathway to approval.

Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3

Androgenetic Alopecia DLQ01 has the potential to become the leading next generation hair growth product. It is a liquid topical formulation of a prostaglandin (PG) F2alpha analog in hyliQ^® designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. DLQ01 Phase 2 data has impressively demonstrated its superior efficacy. The number of hairs in the target area increased effectively with high statistical significance compared to the vehicle. More than 80% of subjects responded with a positive change in hair growth. We are continuing clinical development based on a clear regulatory pathway to approval.

DLQ01

DLQ02

Alopecia Areata
Alopecia Areata (AA) is a chronic immune-mediated condition affecting up to 2% of the global population.

It is characterized by autoimmune, chronic, and relapsing hair loss ranging from scattered patches to complete loss of hair, with significant psychological impact. At present, there are only two approved systemic drugs, which have a limited response rate. There is a high unmet medical need for safe topical applications, especially for mild and moderate forms of AA that only affect small areas of the scalp.

DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of immune-mediated conditions. DLQ02 offers a dual mode of action, combining immunomodulation with hirsutism, which promotes additional hair growth.

We plan to initiate a phase 2a study in Alopecia Areata by Q4/2024

Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3

Alopecia Areata Alopecia Areata (AA) is a chronic immune-mediated condition affecting up to 2% of the global population. It is characterized by autoimmune, chronic, and relapsing hair loss ranging from scattered patches to complete loss of hair, with significant psychological impact. At present, there are only two approved systemic drugs, which have a limited response rate. There is a high unmet medical need for safe topical applications, especially for mild and moderate forms of AA that only affect small areas of the scalp. DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of immune-mediated conditions. DLQ02 offers a dual mode of action, combining immunomodulation with hirsutism, which promotes additional hair growth. We plan to initiate a phase 2a study in Alopecia Areata by Q4/2024

DLQ02

DLQ03

Acceleration of wound healing and prevention of secondary skin infections

DLQ03 is a differentiated topical drug candidate, targeting accelerated wound healing and the prevention of secondary infections and to support the injured skin barrier. Burn wounds, but also artificial wounds after aesthetic procedures such as lasers, chemical peels, injections and surgery etc. are invasive and carry the risk of secondary infections and scarring.

DLQ03 Phase 2 data in human impressively demonstrated its superior efficacy in accelerating wound healing which was achieved 20-25% faster compared to vehicle.

Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3

Acceleration of wound healing and prevention of secondary skin infections DLQ03 is a differentiated topical drug candidate, targeting accelerated wound healing and the prevention of secondary infections and to support the injured skin barrier. Burn wounds, but also artificial wounds after aesthetic procedures such as lasers, chemical peels, injections and surgery etc. are invasive and carry the risk of secondary infections and scarring. DLQ03 Phase 2 data in human impressively demonstrated its superior efficacy in accelerating wound healing which was achieved 20-25% faster compared to vehicle.